Blueprint Medicines announced the appointment of Kathryn (Kate) Haviland as Chief Business Officer. Ms. Haviland will join the executive management team and will be responsible for Blueprint Medicines' corporate strategy, business development, corporate communications and investor relations functions. Ms. Haviland joins Blueprint Medicines from Idera Pharmaceuticals, where she served as Vice President, Rare Diseases and Oncology Program Leadership.

In this role, she oversaw all aspects of the product development strategy for Idera Pharmaceuticals' rare disease and oncology pipeline programs, including preclinical research, manufacturing and drug supply, regulatory affairs, clinical development and execution, and commercial planning. The company also announced that Anthony (Andy) Boral, M.D., Ph.D., has been promoted to Chief Medical Officer. Dr. Boral joined Blueprint Medicines in February 2015 as Senior Vice President, Clinical Development, and has been instrumental in building Blueprint Medicines clinical development organization and advancing BLU-554 and BLU-285 into Phase 1 clinical trials.

Prior to joining Blueprint Medicines, Dr. Boral was Executive Director, Oncology Clinical Research at the Novartis Institutes for BioMedical Research, or Novartis, and also served as Deputy Site Head for Novartis's Cambridge, Massachusetts location.